AR and prostate carcinoma: After a preliminary stage of hormone-sensitive disease that is treated by androgen-deprivation therapy and agents directly inactivating the AR, patients progress to castrate resistant prostate cancer (CRPC) for which there is no curative treatment available with an extremely poor prognosis.